Stephen Fillman, MD
Internal Medicine · Shenandoah, TXNPI 1992779961
Payments from drug & device makers
Across 285 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$352
- AbbVie$323
- Pfizer$307
- Boehringer Ingelheim$292
- GSK$272
- plus $2K from 34 others
What the payments were for
- Food & beverage$4,82999%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 78 | $1,028 |
| Lilly USA, LLC | 22 | $352 |
| AbbVie(2 entities) | 21 | $323 |
| Pfizer | 15 | $307 |
| Boehringer Ingelheim | 19 | $292 |
| GSK | 15 | $272 |
| Bayer | 11 | $236 |
| Amgen | 15 | $228 |
| Abbott | 3 | $214 |
| Novartis | 11 | $180 |
| AstraZeneca(2 entities) | 9 | $151 |
| Esperion Therapeutics, Inc. | 7 | $138 |
| Lucid Diagnostics Inc. | 1 | $117 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $109 |
| Amarin Pharma, Inc. | 5 | $98 |
| Radius Health, Inc. | 5 | $90 |
| Astellas Pharma US Inc | 5 | $81 |
| Exact Sciences | 3 | $50 |
| Verity Pharmaceuticals Inc. | 2 | $49 |
| Merck | 3 | $44 |
| Sunovion Pharmaceuticals Inc. | 4 | $42 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $40 |
| Almatica Pharma LLC | 2 | $37 |
| Vivus LLC | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 1 | $32 |
| Edwards Lifesciences | 1 | $31 |
| Johnson & Johnson | 1 | $30 |
| Supernus Pharmaceuticals, Inc. | 2 | $26 |
| Dexcom, Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Abiomed | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Evoke Pharma, Inc. | 1 | $19 |
| Clarus Therapeutics Inc. | 1 | $17 |
| Tolmar, Inc. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Confirm Rx$177
How this compares
$4,861 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 161 | $207,861 |
| JardianceEmpagliflozin | 94 | $121,992 |
| Teriparatide | 29 | $68,608 |
| RybelsusSemaglutide | 41 | $60,876 |
| EliquisApixaban | 42 | $59,705 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 40 | $50,139 |
| MounjaroTirzepatide | 38 | $39,719 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $33,828 |
| EntrestoSacubitril/Valsartan | 22 | $28,799 |
| MyrbetriqMirabegron | 38 | $28,216 |
| XareltoRivaroxaban | 17 | $26,364 |
| TrulicityDulaglutide | 16 | $26,187 |
| FarxigaDapagliflozin Propanediol | 18 | $25,738 |
| GemtesaVibegron | 37 | $25,016 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 18 | $21,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,028 | $268,737202 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $292 | $172,130134 claims |
| PfizerEliquis, Premarin | $307 | $68,07356 claims |
| Lilly USA, LLCMounjaro, Trulicity | $352 | $65,90654 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $272 | $55,09357 claims |
| AstraZenecaFarxiga, Symbicort | $151 | $30,81635 claims |
| NovartisEntresto | $180 | $28,79922 claims |
| Astellas Pharma US IncMyrbetriq | $81 | $28,21638 claims |
| Johnson & JohnsonXarelto | $30 | $26,36417 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $34 | $21,22818 claims |
| MerckJanumet Xr | $44 | $16,74523 claims |
| AbbVieSynthroid | $323 | $12,021217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Shenandoah
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.